Reduction in Basic Fibroblast Growth Factor Mediated Angiogenesis In Vivo by Linomide

References

• Ilback N. G., Fohlman J., Slorach S., Firman G. Effects of the immunomodular LS 2616 on T-lymphocyte subpopulations in murine coxsackievirus B3 myocarditis. J. Immunol. 1989; 142: 3225–3228
   PubMed Web of Science ®Google Scholar
• Larsson E. L., Joki A., Stalhandske T. Mechanism of action of the new immunomodulator LS 2616 on T-cell responses. Int. J. Immunopharmacol. 1987; 9: 425–431
   PubMed Web of Science ®Google Scholar
• Kalland T., Aim G., Stalhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors. J. Immunol. 1990; 144: 4472–4476
   PubMed Web of Science ®Google Scholar
• Condiotti R., Slavin S., Barak V., Nagler A. The novel immunomodulator, Linomide, stimulates interleukin-2 induced human natural killer (NK) cell and PHA-stimulated T-cell proliferation from normal donors. Leuk. Res. 1996; 20: 57–63
   PubMed Web of Science ®Google Scholar
• Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 1986; 46: 3018–3022
   PubMed Web of Science ®Google Scholar
• Harning R., Koo G. C., Szalay J. Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest. Ophtalmol. Pothalmol. Vis. Sci. 1989; 30, 1909-1915.
   Google Scholar
• Harning R., Koo G. C., Szalay J. Immune regulation of metastasis from in vivo derived syngeneic murine melanoma. Reg. Immunol. 1990; 3: 97–102
   PubMedGoogle Scholar
• Kalland T., Aim G., Stalhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Ter-Grigorov V., Slavin S., Liubashevsky E., Trainin S. Successful treatment of Rauscher retrovirus-induced leukemia in mice with the immunomodulator LS 2616, (submitted)
   Google Scholar
• Stalhandske T., Eriksoo E., Sandberg M. A. A novel quinolinecarboxamide with interesting immunomodulatory activity. Int. J. Immunopharmacol. 1982; 4: 336–341
   Web of Science ®Google Scholar
• Ichikawa T. M., Lamb J. C., Christensson P. J., Hartley-Asp B., Isaacs J. T. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 1992; 52: 3022–3028
   PubMed Web of Science ®Google Scholar
• Rowe J. U., Ryan D. H., Nilsson B. I., Liesveld J. L., DePersio J. F., Rapport A. P., Abbound C. N., Larsson L., Packman C. H., Duerst R. E., Simonsson B. Chronic myelogenous leukemia treated with autologous bone marrow transplantation followed by Roquinimex. Blood 1994; 10: 204a, (abst.).
   Google Scholar
• Vukanovic J., Passaniti A., Hirata T., Traystman R. J., Hartley-Asp B., Isaacs J. T. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 1993; 53: 1833–1837
   PubMed Web of Science ®Google Scholar
• Vukanovic J., Isaacs J. T. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 1995; 55: 3517–3520
   PubMed Web of Science ®Google Scholar
• Vukanovic J., Hartley-Asp B., Isaacs J. T. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate 1995; 26: 235–246
   PubMed Web of Science ®Google Scholar
• Vukanovic J., Isaacs J. T. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995; 55: 1499–1504
   PubMed Web of Science ®Google Scholar
• Borgstrom P., Torres Filho I. P., Hartley-Asp B. Inhibition of angiogenesis and metastasis of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide. Anticancer Res 1995; 15: 719–728
   PubMed Web of Science ®Google Scholar
• Joseph I. B., Vukanovic J., Isaacs J. T. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 1996; 56: 3404–3408
   PubMed Web of Science ®Google Scholar
• Folkman J. Towards an understanding of angiogenesis: search and discovery. Perspectives, in Biology and Medicine 1985; 29: 1–36
   PubMedGoogle Scholar
• Folkman J., Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–447
   PubMed Web of Science ®Google Scholar
• Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992; 267: 10–10, 931934
   Google Scholar
• Gospodarowicz D., Cheng J., Lui G. M. Isolation of brain fibroblast growth factor by heparin-sepharose affinity chromography: identity with pituitary fibroblast growth factor. Proc. Natl. Acad. Sci. 1984; 81: 6963–6967
   PubMed Web of Science ®Google Scholar
• Gospodarowicz D., Moran J., Braun D., Birdwell C. R. Clonal growth of bovine vascular endothelial cells in tissue culture: fibroblast growth factor as a survival agent. Proc. Natl. Acad. Sci. 1976; 73: 4120–4124
   PubMed Web of Science ®Google Scholar
• Vlodavsky I., Liu G. M., Gospodarowicz D. Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix vs. plastic. Cell 1980; 19: 607–616
   PubMed Web of Science ®Google Scholar
• Vlodavsky I., Folkman J., Sullivan R., Friedman R., Ishai-Michaeli R., Sasse J., Klagsbrun M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. 1987; 84: 2292–2296
   PubMed Web of Science ®Google Scholar
• Burton K. Determination of DNA concentration with diphenyl amine. Meth. Enzymol. 1968; XII-B: 163–166
   Google Scholar
• Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Stegemann H., Stalder K. Determination of hydrox-yproline. Clin. Chim. Acta 1967; 18: 267–273
   PubMed Web of Science ®Google Scholar
• Neuman R. E., Logan M. H. The determination of collagen and elastin in tissue. J. Biol. Chem. 1950; 186: 549–556
   PubMed Web of Science ®Google Scholar
• Deujanov I. Biology of disease. Lectin cytochemistry and histochemistry. Lab. Invest. 1987; 57: 5–20
   PubMed Web of Science ®Google Scholar
• Kivela T. Characterization of galactose-containing glycoconjugates in the human retina: a lectin histochemical study. Current Eye. Res. 1990; 9: 1195–1209
   PubMed Web of Science ®Google Scholar
• Marani A. Methods of planning and conduction of experiments. Academon Press, Jerusalem) 1972; 33
   Google Scholar
• Borgstrom P., Torres Filho I. P., Vajkoczy P., Strandgarden K., Polacek J., Hartley-Asp B. The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol. 1994; 34: 280–286
   PubMed Web of Science ®Google Scholar
• Joseph I. B., Isaacs J. T. The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. Prostate 1996; 29: 183–190
   PubMed Web of Science ®Google Scholar
• Parenti A., Donnini S., Morbidelli L., Granger H. J., Ziche M. The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor. Br. J. Pharmacol 1996; 119: 619–621
   PubMed Web of Science ®Google Scholar
• Bischoll J. Approaches to studying cell adhesion molecules in angiogenesis. Trends. Cell. Biol. 1995; 5: 69–74
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe M. L., Hasselaar P. Differential expression of extra-cellular proteins in correlation with angiogenesis in vitro. Lab. Invest. 1991; 64: 174–186
   PubMed Web of Science ®Google Scholar
• Jackson C. J., Jenkins K. L. Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp. Cell Res. 1991; 192: 319–323
   PubMed Web of Science ®Google Scholar
• Slavin S., Naparstek E., Nagler A., Ackerstein A., Samuel S., Kapelushnik J., Brautbar C., Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204
   PubMed Web of Science ®Google Scholar
• Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheal blood lymphocytes. Exp. Hematol. 1995; 23: 1553–1562
   PubMed Web of Science ®Google Scholar
• Nagler A., Ackerstein A., Or R., Naparstek E., Slavin S. Immunotherapy with recombinant human interleukin-2 (rIL-2) and recombinant alpha interferon (αIFN) in lymphoma patients post-autologous marrow or stem cell transplantation. Blood 1997; 89: 3951–3959
   PubMed Web of Science ®Google Scholar